AstraZeneca's Imfinzi gained a positive opinion from the EMA for treating resectable non-small cell lung cancer, showing reduced recurrence and consistent safety in the Aegean trial.
Goldman Sachs has added AstraZeneca to its European conviction list, reflecting a positive outlook for the company's stock.
As of February 28, 2025, AstraZeneca PLC has 1,550,607,175 ordinary shares with voting rights and no shares held in Treasury, per UK Financial Conduct Authority rules.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.